AFAR's Mission

To support and advance Healthy Aging through Biomedical Research

Watch our Live Longer, Live Well video (right) to explore how a better world for older people is a better world for everyone.

SA Home Page 2col Art



Celebrating and studying
exceptional longevity

Enroll in the SuperAgers Family Study and explore related research and resources

Learn more

AFAR's Grant Programs

42

Years

4400

Talented Investigators

$

200

Million Funded

Green Spotlight Microscope

Investing in Talent

Novel Interventions

Believing in Innovation

AFAR News

New York Times News Item Logo Template
Leadership in the News: Executive Director Stephanie Lederman in The New York Times on support for the Dog Aging Project
Med Page News Item Logo Template Whitebox
Leadership in the News: Scientific Director Nir Barzilai, MD, in MedPage on Biological Age and SuperAgers amid scrutiny of Presidential Candidates’ Ages.
Chicago Sun Times News Item Logo
AFAR SuperAgers Family Study featured in Chicago Sun Times
Dog Aging Project News Item Logo Template Whitebox
AFAR encourages petition to Renew NIH Support for The Dog Aging Project
New York Times News Item Logo Template
AFAR Leadership in the News: Scientific Director Nir Barzilai, MD, on biological age in The New York Times
AFAR News
2023 Clin-STAR and Beeson Meetings Wrap-Up
AFAR News Social Art AFARISHIRING2

Communications and Development Assistant

Learn more

AFAR's Leadership

AFAR provides infrastructure support and leadership for three initiatives funded by the National Institute on Aging (NIA).

NSC Whitebox

Providing leadership in the pursuit of basic research into the biology of aging

RCCN White Box

Catalyzing cross-disciplinary research across the NIA center programs

Clin STAR White Box

A national platform to advance transdisciplinary aging research

The TAME Trial

The AFAR-managed TAME (Targeting Aging with Metformin) Trial will establish a proof-of-concept that aging processes can be treated, just as we treat diseases.

The TAME Trial ultimately seeks the FDA to make aging an "indication" for treatment.

If aging is made an indication, the TAME Trial will mark a paradigm shift: from treating each age-related medical condition separately, to treating these conditions together, by targeting aging per se.

Learn about the TAME Trial
Public statements by individual AFAR employees, affiliates, or Board members do not imply endorsement by AFAR. AFAR’s viewpoints are expressed only through official releases after approval by its Executive Director or Board of Directors.

Stay Connected

For updates on AFAR experts, events, articles, and more, subscribe to our newsletter, EncourAGE.

Sign up for Updates here

A Healthier Tomorrow
Starts Today

AFAR-supported investigators are advancing research that will help us all live healthier, longer. Your support is vital to help strengthen the vital research pipeline.

Giving Opportunities

AFAR is grateful for the collaboration and support of our program partners, including:

Gilbert White Box
Glenn White Box


David Gore

Hevolution whitebox
Mc Knight Whitebox
Sagol Whitebox

AFAR is proud to consistently receive the highest ratings from respected charity evaluators

CharityNavigator4StarBadge.png
Guidestar Sealof Transparency